Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | KD033 |
Synonyms | |
Therapy Description |
KD033 is a fusion protein consisting of a PD-L1 (CD274) antibody fused to human IL-15, which potentially results in increased T-cell tumor infiltration and inhibition of tumor growth (J Clin Oncol 39, no. 15_suppl.e14556; J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2568). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KD033 | KD 033|KD-033 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | KD033 is a fusion protein consisting of a PD-L1 (CD274) antibody fused to human IL-15, which potentially results in increased T-cell tumor infiltration and inhibition of tumor growth (J Clin Oncol 39, no. 15_suppl.e14556; J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2568). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04242147 | Phase I | KD033 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. | Terminated | USA | 0 |